Phase 1 Multicenter, Randomized, Double-Blind, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus

Trial Profile

Phase 1 Multicenter, Randomized, Double-Blind, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Jun 2015

At a glance

  • Drugs PE 0139 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; First in man
  • Sponsors PhaseBio Pharmaceuticals
  • Most Recent Events

    • 09 Jun 2015 Interim results (n=8) presented at the 75th Annual Scientific Sessions of the American Diabetes Association.
    • 08 Jun 2015 Results of this study were published in a PhaseBio Pharmaceuticals media release.
    • 08 Jun 2015 According to a PhaseBio Pharmaceuticals media release, positive data of this study was presented at the American Diabetes Association 75th Scientific Sessions 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top